Intra Cellular Therapies | Ativo Circulante



Ativo Circulante Alterar Data
Acadia Pharmaceuticals USD 1.08B 115.87M 2025-09
ALKERMES USD 1.74B 106.38M 2025-09
BioCryst Pharmaceuticals USD 355.68M 42.78M 2025-09
Biogen USD 8.97B 37.5M 2025-12
Bristol-Myers Squibb USD 35.63B 2.41B 2025-09
Cytokinetics USD 977.35M 90.81M 2025-09
Esperion Therapeutics USD 360.46M 17.87M 2025-09
Gilead Sciences USD 19.89B 1.05B 2025-12
Halozyme Therapeutics USD 825.21M 503.54M 2025-12
J&J USD 55.62B 1.01B 2025-12
Minerva Neurosciences USD 13.02M 2.53M 2025-09
Nektar Therapeutics USD 281.36M 94.79M 2025-09
Neurocrine Biosciences USD 2.52B 364.3M 2025-12
Novartis USD 28.2B 2.26B 2025-09
Prothena USD 339.97M 45.51M 2025-09
RedHill Biopharma USD 12.56M 644K 2025-06
Supernus Pharmaceuticals USD 593.89M 144.98M 2025-09
United Therapeutics USD 3.49B 332.9M 2025-09
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12


Intra Cellular Therapies Ativo Circulante - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - Feb 2026.